Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
Document Type
Journal Article
Publication Date
1-15-2017
Journal
The Journal of Infectious Diseases
Volume
215
Issue
2
Inclusive Pages
384-393
DOI
10.1093/infdis/jiw525
Keywords
Adolescent; Adult; Aged; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Disease Transmission, Infectious; Double-Blind Method; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Prospective Studies; Triazoles; Young Adult
APA Citation
Gulick, R., Wilkin, T., Chen, Y., Landovitz, R., Amico, K., Young, A., Richardson, P., Marzinke, M., Hendrix, C., Eshleman, S., McGowan, I., Cottle, L., Andrade, A., Marcus, C., Klingman, K., Chege, W., Rinehart, A., Rooney, J., Andrew, P., Salata, R., Magnus, M., Farley, J., Liu, A., Frank, I., Ho, K., Santana, J., Stekler, J., McCauley, M., & Mayer, K. (2017). Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).. The Journal of Infectious Diseases, 215 (2). http://dx.doi.org/10.1093/infdis/jiw525
Peer Reviewed
1
Open Access
1
Comments
This is an open access PubMed Central article.